Corient Private Wealth LLC Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Corient Private Wealth LLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,271 shares of the biotechnology company's stock, valued at approximately $450,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth $30,000. Jones Financial Companies Lllp lifted its stake in shares of Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after buying an additional 197 shares in the last quarter. Blue Trust Inc. boosted its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 328 shares during the last quarter. Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at about $60,000. Finally, GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded up $0.72 on Wednesday, reaching $152.15. The company had a trading volume of 494,277 shares, compared to its average volume of 468,034. The firm's 50 day moving average price is $145.65 and its two-hundred day moving average price is $137.96. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The firm has a market cap of $9.23 billion, a PE ratio of -21.43 and a beta of 0.61.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective on the stock. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a report on Tuesday, February 18th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $204.64.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.